隔离器联动技术保障注射剂药品质量安全

赛进(中国)制药有限公司副总裁、研发中心总经理田欣欣博士论坛发言

文章来源:弗戈工业在线 发布时间:2015-06-04
赛进(中国)制药有限公司副总裁、研发中心总经理田欣欣博士论坛发言

由德国弗戈工业媒体主办的“2015弗戈制药工程国际论坛”于6月4日在江苏泰州举行。论坛汇集PROCESS《流程工业》杂志全球(德文版、英文版、印度版)力量,采用主会场与分论坛相结合,力求营造重点突出、主题明确的专业学术氛围。以下是赛进(中国)制药有限公司副总裁、研发中心总经理田欣欣博士在2015弗戈制药工程国际论坛上关于“隔离器联动技术保障注射剂药品质量安全”的发言。


演讲现场

关于田欣欣博士:

现任赛进(中国)制药有限公司研发副总裁,赛进制药研发中心总经理,毕业于伊利诺伊大学, 获得制药博士学位,曾任职于欧美多家知名国际制药公司,在注射剂产品开发与产品技术转移方面拥有近20年的专业经验。

Dr. Shane TIAN is currently Vice President and General Manager of R&D Center for Sagent China PharmaceuticalsLtd (SCP) in Chengdu, China. He obtained his Ph.D. in pharmacy from the University ofIllinois in Chicago (UIC) and has over 20 years of experiences in drug product developmentand technology transfers, particularly with sterile injectables. Prior to SCP, He worked forseveral pharmaceutical companies in the US, including APP, Purdue Pharma, Eyetech andSanofi. He is also a member of the Parenteral Drug Association (PDA). Shane Joined Sagent China and moved to Chengdu in Nov 2010. In April 2013, SCP received the official FDA approval for supplying injectable drug products to the Unites States. In 2014, SCP received first FDA CBE 30 site transfer for liquid Injectables in China. In 2015, SCP received the first FDA CBE30 site transfer for Lyophilized Injectables.

0
-1
收藏